MedPacto Presents Clinical Results of 'Vactosertib' at Sarcoma Symposium

MedPacto, an innovative new drug development company, announced on the 21st that it participated in the 4th Korean INnovative Group for Sarcoma research (KINGS) Symposium held at Koreana Hotel in Seoul on the 20th, where it presented clinical results and future plans for its osteosarcoma candidate substance, vactosertib.

The 'KINGS Symposium' is an academic event organized by the KINGS research group, which was established with support from the National Cancer Center Development Fund, the National Institute of Health under the Korea Disease Control and Prevention Agency, and the National Cancer Center's Rare Cancer Research Project Group. The event aims to share diverse research achievements in the field of sarcoma both domestically and internationally, and to promote networking and collaboration among researchers.

At the event, Kim Sungjin, CEO of MedPacto, was invited as a keynote speaker and gave a presentation titled "Innovative Insights and Therapeutic Strategies for the Malignant Transformation Process in Sarcoma."

Kim Sungjin, CEO of MedPacto, explained, "In sarcoma, the role of the TGF-β pathway functions differently compared to typical solid tumors. Most sarcoma cells do not respond to TGF-β signaling but secrete large amounts of TGF-β1, altering the tumor microenvironment and thereby promoting cancer growth and metastasis. Regulating this process is key to treatment."

Basing his remarks on research outcomes published in international journals, Kim stated, "Since vactosertib monotherapy has shown groundbreaking efficacy in osteosarcoma, it also holds high therapeutic potential for other types of sarcoma, such as Ewing sarcoma, alveolar rhabdomyosarcoma (ARMS), and congenital fibrosarcoma."

Alongside the presentation, MedPacto discussed future clinical plans with leading professors from major hospitals in Korea and representatives from the National Cancer Center Japan (NCCJ), as well as other domestic and international sarcoma experts.

Sarcoma is a type of cancer that develops in soft tissues or bones that support and connect the body, such as cartilage, muscle, fat, blood vessels, and nerves. Unlike most cancers, which are epithelial, sarcomas originate from mesenchymal tissue and are characterized by the difficulty in identifying their causes and treating them.

MedPacto has recently attracted attention by presenting clinical results on complete remission (CR) in osteosarcoma patients using its anticancer drug candidate, vactosertib, at international conferences.

This content was produced with the assistance of AI translation services.